Chi Young Jung

1.1k total citations
38 papers, 520 citations indexed

About

Chi Young Jung is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Surgery. According to data from OpenAlex, Chi Young Jung has authored 38 papers receiving a total of 520 indexed citations (citations by other indexed papers that have themselves been cited), including 26 papers in Pulmonary and Respiratory Medicine, 13 papers in Oncology and 5 papers in Surgery. Recurrent topics in Chi Young Jung's work include Lung Cancer Treatments and Mutations (17 papers), Lung Cancer Diagnosis and Treatment (10 papers) and Lung Cancer Research Studies (7 papers). Chi Young Jung is often cited by papers focused on Lung Cancer Treatments and Mutations (17 papers), Lung Cancer Diagnosis and Treatment (10 papers) and Lung Cancer Research Studies (7 papers). Chi Young Jung collaborates with scholars based in South Korea, Ireland and United States. Chi Young Jung's co-authors include Kyung Chan Kim, Eun Jin Kim, Jung‐Yoon Choe, Scott Antonia, Hyun Hee Kwon, Hyo‐Lim Hong, JW Kim, Jin Seok Ahn, Jae Hyun Jeon and Ho Cheol Kim and has published in prestigious journals such as Annals of Oncology, The Journals of Gerontology Series A and Medicine.

In The Last Decade

Chi Young Jung

35 papers receiving 510 citations

Peers

Chi Young Jung
Dionysios Koliogiannis Germany
Zhenju Song China
Ravi Taneja Canada
Pascal Pernet France
Marta Martín-Fernández Spain
Jianqing She China
Dionysios Koliogiannis Germany
Chi Young Jung
Citations per year, relative to Chi Young Jung Chi Young Jung (= 1×) peers Dionysios Koliogiannis

Countries citing papers authored by Chi Young Jung

Since Specialization
Citations

This map shows the geographic impact of Chi Young Jung's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Chi Young Jung with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Chi Young Jung more than expected).

Fields of papers citing papers by Chi Young Jung

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Chi Young Jung. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Chi Young Jung. The network helps show where Chi Young Jung may publish in the future.

Co-authorship network of co-authors of Chi Young Jung

This figure shows the co-authorship network connecting the top 25 collaborators of Chi Young Jung. A scholar is included among the top collaborators of Chi Young Jung based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Chi Young Jung. Chi Young Jung is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Lim, Jeong Uk, Ho Cheol Kim, Tae Jung Kim, et al.. (2025). Comparison of metastasis and treatment patterns among different histopathologic types of lung cancer: analysis of 6 years of nationwide lung cancer cohort data in Korea. Translational Lung Cancer Research. 14(2). 363–384.
2.
Park, Cheol‐Kyu, Seung Joon Kim, Chan Kwon Park, et al.. (2024). Real‐world outcome of crizotinib for anaplastic lymphoma kinase‐positive lung cancer: Multicenter retrospective analysis in South Korea. Thoracic Cancer. 15(6). 448–457. 2 indexed citations
3.
Park, Ji Eun, Kyung Soo Hong, Sun Ha Choi, et al.. (2024). Durvalumab Consolidation After Chemoradiotherapy in Elderly Patients With Unresectable Stage III NSCLC: A Real-World Multicenter Study. Clinical Lung Cancer. 25(4). 354–364. 6 indexed citations
4.
Choi, Tae Young, et al.. (2023). Impact of a Psychiatric Consultation Program on COVID-19 Patients: An Experimental Study. Psychiatry Investigation. 20(5). 471–480. 2 indexed citations
5.
Choi, Juwhan, Chang‐Min Choi, Yoon Soo Chang, et al.. (2023). Real-world first-line afatinib for advanced EGFR mutation-positive non-small cell lung cancer in Korea: updated survival data. Translational Lung Cancer Research. 12(11). 2275–2282.
6.
Kim, Ho Cheol, Se Hee Kim, Tae Jung Kim, et al.. (2022). Five-Year Overall Survival and Prognostic Factors in Patients with Lung Cancer: Results from the Korean Association of Lung Cancer Registry (KALC-R) 2015. Cancer Research and Treatment. 55(1). 103–111. 56 indexed citations
7.
Kang, Hye Seon, Jeong Uk Lim, Chang Dong Yeo, et al.. (2022). Characteristics and clinical outcomes of patients with nonsmoking small cell lung cancer in Korea. BMC Pulmonary Medicine. 22(1). 200–200. 6 indexed citations
8.
Jung, Chi Young, et al.. (2021). Using Virtual Pet to Replace Pet Therapy Visits in Our Nursing Facility During the COVID-19 Pandemic. Journal of the American Medical Directors Association. 22(3). B18–B18. 3 indexed citations
9.
Lee, Sung Yong, Chang‐Min Choi, Yoon Soo Chang, et al.. (2021). Real-world experience of afatinib as first-line therapy for advanced EGFR mutation-positive non-small cell lung cancer in Korea. Translational Lung Cancer Research. 10(12). 4353–4367. 11 indexed citations
10.
Kim, JW, Eun Jin Kim, Hyun Hee Kwon, et al.. (2020). Lopinavir-ritonavir versus hydroxychloroquine for viral clearance and clinical improvement in patients with mild to moderate coronavirus disease 2019. The Korean Journal of Internal Medicine. 36(Suppl 1). S253–S263. 29 indexed citations
11.
Lim, Jeong Uk, Ho Cheol Kim, Chang‐Min Choi, et al.. (2020). Characteristics of female lung cancer in Korea: analysis of Korean National Lung Cancer Registry. Journal of Thoracic Disease. 12(9). 4612–4622. 6 indexed citations
12.
Kim, Eun Jin, Eun‐Hyung Yoo, Chi Young Jung, & Kyung Chan Kim. (2020). Experience of percutaneous tracheostomy in critically ill COVID-19 patients. Acute and Critical Care. 35(4). 263–270. 3 indexed citations
13.
Choi, Chang‐Min, Ho Cheol Kim, Chi Young Jung, et al.. (2019). Report of the Korean Association of Lung Cancer Registry (KALC-R), 2014. Cancer Research and Treatment. 51(4). 1400–1410. 51 indexed citations
14.
Kim, Ho Cheol, Chi Young Jung, Deog Gon Cho, et al.. (2018). Clinical Characteristics and Prognostic Factors of Lung Cancer in Korea: A Pilot Study of Data from the Korean Nationwide Lung Cancer Registry. Tuberculosis & respiratory diseases. 82(2). 118–118. 48 indexed citations
15.
Jung, Chi Young, Sang Yeub Lee, Woo Jin Kim, et al.. (2018). Use of serology and polymerase chain reaction to detect atypical respiratory pathogens during acute exacerbation of chronic obstructive pulmonary disease. The Korean Journal of Internal Medicine. 33(5). 941–951. 8 indexed citations
16.
Jung, Chi Young, Soyoung Kim, & ChuHee Lee. (2018). Carvacrol Targets AXL to Inhibit Cell Proliferation and Migration in Non-small Cell Lung Cancer Cells. Anticancer Research. 38(1). 279–286. 32 indexed citations
17.
Won, Seung, Yong Soo Kwon, Sung Ho Yoon, et al.. (2017). Sputum bacteriology and clinical response to antibiotics in moderate exacerbation of chronic obstructive pulmonary disease. The Clinical Respiratory Journal. 12(4). 1424–1432. 7 indexed citations
18.
Park, Cheol‐Kyu, In‐Jae Oh, Kyu-Sik Kim, et al.. (2017). Randomized Phase III Study of Docetaxel Plus Cisplatin Versus Pemetrexed Plus Cisplatin as First-line Treatment of Nonsquamous Non–Small-cell Lung Cancer: A TRAIL Trial. Clinical Lung Cancer. 18(4). e289–e296. 18 indexed citations
19.
Jung, Chi Young, Jin Eun Choi, Jung Min Park, et al.. (2006). Polymorphisms in thehMSH2Gene and the Risk of Primary Lung Cancer. Cancer Epidemiology Biomarkers & Prevention. 15(4). 762–768. 34 indexed citations
20.
Jung, Chi Young, Jae Hee Lee, Hyo Sung Jeon, et al.. (2003). The GSTT1 Genotype as A Marker for Susceptibility to Lung Cancer in Korean Female Never-Smokers. Tuberculosis and Respiratory Diseases. 54(5). 485–485. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Dionysios Koliogiannis Breakdown of academic impact, for papers by Zhenju Song Breakdown of academic impact, for papers by Ravi Taneja Breakdown of academic impact, for papers by Pascal Pernet Breakdown of academic impact, for papers by Marta Martín-Fernández Breakdown of academic impact, for papers by Jianqing She
Rankless by CCL
2026